Phathom Pharmaceuticals, Inc.

PHAT

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001783183

SEC filings (opens in a new tab)

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of PHAT: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	114	1	133	+20
Shares	58.1M	2.93M	72.6M	+17.5M (+31.6%)
Value	$598.6M	$30.1M	$1.31B	+$744.3M (+130.9%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (30)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to PHAT in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	3,122,570	$56.5M	0.00%
OrbiMed Advisors LLC	1,449,073	$26.2M	0.48%
Federated Hermes, Inc.	1,403,638	$25.4M	0.06%
Siren, L.L.C.	460,753	$8.33M	0.42%
Point72 Asset Management, L.P.	439,816	$7.95M	0.03%
Wasatch Advisors Inc	246,942	$4.46M	0.02%
EAM Investors, LLC	216,448	$3.91M	0.59%
Susquehanna International Group, LLP	178,670	$3.23M	0.01%
D. E. Shaw & Co., Inc.	143,707	$2.60M	0.00%
ExodusPoint Capital Management, LP	69,282	$1.25M	0.01%
Numerai GP LLC	49,327	$891.8K	0.24%
Tudor Investment Corp Et Al	36,383	$657.8K	0.01%
SEI Investments Co	33,898	$612.9K	0.00%
Millennium Management LLC	32,928	$595.3K	0.00%
Summit Financial Wealth Advisors, LLC	29,032	$524.9K	0.10%
Chartwell Investment Partners, LLC	21,904	$396.0K	0.01%
Keybank National Association	18,043	$326.2K	0.00%
Simplex Trading, LLC	15,698	$283.0K	0.01%
Cowen and Company, LLC	15,000	$271.2K	0.01%
SG Americas Securities, LLC	13,483	$244.0K	0.00%
Intech Investment Management LLC	11,443	$206.9K	0.00%
Quest Partners LLC	10,918	$197.4K	0.02%
Arizona State Retirement System	10,814	$195.5K	0.00%
ProShare Advisors LLC	10,485	$189.6K	0.00%
Public Employees Retirement Association of Colorado	840	$15.0K	0.00%
Larson Financial Group LLC	647	$11.7K	0.00%
ADAR1 Capital Management, LLC	200	$3.62K	0.00%
Sterling Capital Management LLC	106	$1.92K	0.00%
Aster Capital Management (DIFC) Ltd	45	$814	0.00%
Capital Performance Advisors LLP	29	$524	0.00%

Sold out (10)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of PHAT in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Takeda Pharmaceutical Co Ltd	1,557,063	$16.0M
Marshall Wace, LLP	112,691	$1.16M
Fulton Breakefield Broenniman LLC	23,579	$242.9K
Brevan Howard Capital Management LP	18,792	$193.6K
Two Sigma Advisers, LP	16,300	$167.9K
EntryPoint Capital, LLC	8,503	$87.6K
FNY Investment Advisers, LLC	5,000	$51.0K
Aquatic Capital Management LLC	500	$5.15K
Bessemer Group Inc	325	$3.00K
Comerica Bank	129	$1.33K

Not filed for Q3 2024 yet (1)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PHAT in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	2,926,373	$30.1M